- Home
- INKT vs LSTA Comparison
INKT vs LSTA Comparison
Compare INKT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- LSTA
- Stock Information
- Founded
- INKT 2017
- LSTA 1980
- Country
- INKT United States
- LSTA United States
- Employees
- INKT N/A
- LSTA N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- LSTA Misc Health and Biotechnology Services
- Sector
- INKT Health Care
- LSTA Health Care
- Exchange
- INKT Nasdaq
- LSTA Nasdaq
- Market Cap
- INKT 28.5M
- LSTA 24.2M
- IPO Year
- INKT 2021
- LSTA N/A
- Fundamental
- Price
- INKT $0.46
- LSTA $2.58
- Analyst Decision
- INKT Strong Buy
- LSTA Strong Buy
- Analyst Count
- INKT 2
- LSTA 1
- Target Price
- INKT $6.50
- LSTA $15.00
- AVG Volume (30 Days)
- INKT 43.7K
- LSTA 19.6K
- Earning Date
- INKT 11-14-2024
- LSTA 11-12-2024
- Dividend Yield
- INKT N/A
- LSTA N/A
- EPS Growth
- INKT N/A
- LSTA N/A
- EPS
- INKT N/A
- LSTA N/A
- Revenue
- INKT N/A
- LSTA N/A
- Revenue This Year
- INKT N/A
- LSTA N/A
- Revenue Next Year
- INKT N/A
- LSTA N/A
- P/E Ratio
- INKT N/A
- LSTA N/A
- Revenue Growth
- INKT N/A
- LSTA N/A
- 52 Week Low
- INKT $0.46
- LSTA $2.19
- 52 Week High
- INKT $1.90
- LSTA $3.83
- Technical
- Relative Strength Index (RSI)
- INKT 15.27
- LSTA 41.13
- Support Level
- INKT $0.64
- LSTA $2.48
- Resistance Level
- INKT $0.67
- LSTA $2.77
- Average True Range (ATR)
- INKT 0.06
- LSTA 0.19
- MACD
- INKT -0.02
- LSTA -0.01
- Stochastic Oscillator
- INKT 0.00
- LSTA 56.52
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.